Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1663746

	registered interest
	date	13/10/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cystic Fibrosis: Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of (a) paediatric and (b) adult cystic fibrosis centres did not provide at least 85 per cent of their patients with psychological support at their annual review in (i) 2021 and (ii) 2022.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	201599
	answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>The information is not available in the requested format.</p><p>However, tables showing that the number of centres where the percentage of adult cystic fibrosis patients and paediatric cystic fibrosis patients seen by a clinical psychologist within 12 months prior to the latest annual review was less than 85% in 2021/2022 and 2022/2023 are displayed below.</p><p>Adult cystic fibrosis patients seen (e.g. annual review screening, in-patient or out-patient consultation) by a clinical psychologist within 12 months prior to latest annual review:</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2021/2022</p></td><td><p>2022/2023</p></td></tr><tr><td><p>Centres reporting data for this indicator during the reporting period</p></td><td><p>12</p></td><td><p>15</p></td></tr><tr><td><p>Number of centres reporting fewer than 85% of patients had seen a psychologist in the 12 months before their latest annual review</p></td><td><p>7</p></td><td><p>10</p></td></tr><tr><td><p>Number of centres reporting that more than 85% of patients had seen a psychologist in the 12 months before their latest annual review</p></td><td><p>5</p></td><td><p>5</p></td></tr></tbody></table><p> </p><p>Paediatric cystic fibrosis patients seen (e.g. annual review screening, in-patient or out-patient consultation) by a clinical psychologist within 12 months prior to latest annual review:</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2021/2022</p></td><td><p>2022/2023</p></td></tr><tr><td><p>Centres reporting data for this indicator during the reporting period</p></td><td><p>16</p></td><td><p>18</p></td></tr><tr><td><p>Number of centres reporting fewer than 85% of patients had seen a psychologist in the 12 months before their latest annual review</p></td><td><p>11</p></td><td><p>14</p></td></tr><tr><td><p>Number of centres reporting that more than 85% of patients had seen a psychologist in the 12 months before their latest annual review</p></td><td><p>5</p></td><td><p>4</p></td></tr></tbody></table><p> </p><p>Source: NHS England Specialised Services Quality Dashboard (SSQD).</p><p> </p><p>SSQD reporting was stood down during the Covid pandemic between April 2020 and March 2022 which may interfere with completeness.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/10/2023 08:30:03 answering member 4423 label Biography information for Will Quince
	tabling member	4397 label Biography information for Peter Dowd

1656170

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Spinal Muscular Atrophy: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of an in-service evaluation for spinal muscular atophy in the NHS on (a) patients and (b) patient families outside of the pilot area.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	196163
	answer	answer is ministerial correction date of answer 11/09/2023 answer text <p>The UK National Screening Committee reviewed screening for spinal muscular atrophy in June 2023. While acknowledging recent developments, it found that more evidence was needed to assess how screening might work safely in the United Kingdom.</p><p>Its recommendation was to develop a new cost effectiveness modelling study for the UK screening context, as well as start scoping in-service evaluation work in live services in the National Health Service in the UK.</p><p>Planning is now underway for the modelling and in-service evaluation, which will help to address these uncertainties and unanswered questions. The UK National Screening Committee will continue to engage with spinal muscular atrophy stakeholders to help shape and input into the work and will keep the public updated via blog articles and ongoing stakeholder engagement.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 196164 196165 196167 196169 196171 196172 question first answered 11/09/2023 13:22:23 answering member 4423 label Biography information for Will Quince
	tabling member	4397 label Biography information for Peter Dowd

1656171

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Spinal Muscular Atrophy: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of opportunities available to the patient community to input into the (a) design and (b) delivery of the UK National Screening Committee’s upcoming in-service evaluation of spinal muscular astrophy screening in the NHS.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	196164
	answer	answer is ministerial correction date of answer 11/09/2023 answer text <p>The UK National Screening Committee reviewed screening for spinal muscular atrophy in June 2023. While acknowledging recent developments, it found that more evidence was needed to assess how screening might work safely in the United Kingdom.</p><p>Its recommendation was to develop a new cost effectiveness modelling study for the UK screening context, as well as start scoping in-service evaluation work in live services in the National Health Service in the UK.</p><p>Planning is now underway for the modelling and in-service evaluation, which will help to address these uncertainties and unanswered questions. The UK National Screening Committee will continue to engage with spinal muscular atrophy stakeholders to help shape and input into the work and will keep the public updated via blog articles and ongoing stakeholder engagement.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 196163 196165 196167 196169 196171 196172 question first answered 11/09/2023 13:22:23 answering member 4423 label Biography information for Will Quince
	tabling member	4397 label Biography information for Peter Dowd

1656172

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Spinal Muscular Atrophy: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) ensure and (b) monitor the (i) introduction, (ii) delivery and (iii) completion of the in-service evaluation for spinal muscular atrophy screening in the NHS.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	196165
	answer	answer is ministerial correction date of answer 11/09/2023 answer text <p>The UK National Screening Committee reviewed screening for spinal muscular atrophy in June 2023. While acknowledging recent developments, it found that more evidence was needed to assess how screening might work safely in the United Kingdom.</p><p>Its recommendation was to develop a new cost effectiveness modelling study for the UK screening context, as well as start scoping in-service evaluation work in live services in the National Health Service in the UK.</p><p>Planning is now underway for the modelling and in-service evaluation, which will help to address these uncertainties and unanswered questions. The UK National Screening Committee will continue to engage with spinal muscular atrophy stakeholders to help shape and input into the work and will keep the public updated via blog articles and ongoing stakeholder engagement.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 196163 196164 196167 196169 196171 196172 question first answered 11/09/2023 13:22:23 answering member 4423 label Biography information for Will Quince
	tabling member	4397 label Biography information for Peter Dowd

1656174

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Spinal Muscular Atrophy: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the UK National Screening Committee commissioning a cost-effectiveness modeling study for spinal muscular atrophy on the timeline for implementing newborn screenings across the UK.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	196167
	answer	answer is ministerial correction date of answer 11/09/2023 answer text <p>The UK National Screening Committee reviewed screening for spinal muscular atrophy in June 2023. While acknowledging recent developments, it found that more evidence was needed to assess how screening might work safely in the United Kingdom.</p><p>Its recommendation was to develop a new cost effectiveness modelling study for the UK screening context, as well as start scoping in-service evaluation work in live services in the National Health Service in the UK.</p><p>Planning is now underway for the modelling and in-service evaluation, which will help to address these uncertainties and unanswered questions. The UK National Screening Committee will continue to engage with spinal muscular atrophy stakeholders to help shape and input into the work and will keep the public updated via blog articles and ongoing stakeholder engagement.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 196163 196164 196165 196169 196171 196172 question first answered 11/09/2023 13:22:23 answering member 4423 label Biography information for Will Quince
	tabling member	4397 label Biography information for Peter Dowd

1656176

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Spinal Muscular Atrophy: Babies
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has made a comparative assessment of health inequalities for babies that have had access to newborn screening for spinal muscular atrophy with those that haven't.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	196169
	answer	answer is ministerial correction date of answer 11/09/2023 answer text <p>The UK National Screening Committee reviewed screening for spinal muscular atrophy in June 2023. While acknowledging recent developments, it found that more evidence was needed to assess how screening might work safely in the United Kingdom.</p><p>Its recommendation was to develop a new cost effectiveness modelling study for the UK screening context, as well as start scoping in-service evaluation work in live services in the National Health Service in the UK.</p><p>Planning is now underway for the modelling and in-service evaluation, which will help to address these uncertainties and unanswered questions. The UK National Screening Committee will continue to engage with spinal muscular atrophy stakeholders to help shape and input into the work and will keep the public updated via blog articles and ongoing stakeholder engagement.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 196163 196164 196165 196167 196171 196172 question first answered 11/09/2023 13:22:23 answering member 4423 label Biography information for Will Quince
	tabling member	4397 label Biography information for Peter Dowd

1656178

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Spinal Muscular Atrophy: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of introducing a permanent newborn screening programme for spinal muscular atrophy on the Government's Life Sciences Vision ambition to make the UK a world leader for (a) access and (b) uptake of new and innovative treatments and technologies.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	196171
	answer	answer is ministerial correction date of answer 11/09/2023 answer text <p>The UK National Screening Committee reviewed screening for spinal muscular atrophy in June 2023. While acknowledging recent developments, it found that more evidence was needed to assess how screening might work safely in the United Kingdom.</p><p>Its recommendation was to develop a new cost effectiveness modelling study for the UK screening context, as well as start scoping in-service evaluation work in live services in the National Health Service in the UK.</p><p>Planning is now underway for the modelling and in-service evaluation, which will help to address these uncertainties and unanswered questions. The UK National Screening Committee will continue to engage with spinal muscular atrophy stakeholders to help shape and input into the work and will keep the public updated via blog articles and ongoing stakeholder engagement.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 196163 196164 196165 196167 196169 196172 question first answered 11/09/2023 13:22:23 answering member 4423 label Biography information for Will Quince
	tabling member	4397 label Biography information for Peter Dowd

1656179

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Spinal Muscular Atrophy: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the UK not having a spinal muscular atrophy screening programme on the development of the UK life science sector.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	196172
	answer	answer is ministerial correction date of answer 11/09/2023 answer text <p>The UK National Screening Committee reviewed screening for spinal muscular atrophy in June 2023. While acknowledging recent developments, it found that more evidence was needed to assess how screening might work safely in the United Kingdom.</p><p>Its recommendation was to develop a new cost effectiveness modelling study for the UK screening context, as well as start scoping in-service evaluation work in live services in the National Health Service in the UK.</p><p>Planning is now underway for the modelling and in-service evaluation, which will help to address these uncertainties and unanswered questions. The UK National Screening Committee will continue to engage with spinal muscular atrophy stakeholders to help shape and input into the work and will keep the public updated via blog articles and ongoing stakeholder engagement.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 196163 196164 196165 196167 196169 196171 question first answered 11/09/2023 13:22:23 answering member 4423 label Biography information for Will Quince
	tabling member	4397 label Biography information for Peter Dowd

1656180

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Spinal Muscular Atrophy: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of introducing newborn screening for spinal muscular atrophy on the priorities of the UK Rare Disease Framework.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	196173
	answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>The Rare Diseases Framework is a high-level document containing overarching priorities and underpinning themes for rare disease policy up to 2025. The Framework is not focused on specific diseases but aims to improve the lives of all people living with rare conditions. As such, no assessment has been made.</p><p>In June 2023, the UK National Screening Committee (UK NSC) recommended that a modelling study be carried out alongside an in-service evaluation of spinal muscular atrophy (SMA) screening in the National Health Service in the United Kingdom. This important work will give the UK NSC the evidence it needs to assess how newborn screening for SMA might work safely in the UK.</p> answering member constituency Colchester answering member printed Will Quince question first answered 08/09/2023 12:11:43 answering member 4423 label Biography information for Will Quince
	tabling member	4397 label Biography information for Peter Dowd

1656181

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Babies: Blood Tests
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has made a comparative assessment of the number of conditions screened under the NHS bloodspot programme with similar programmes in other European countries.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	196174
	answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>The UK National Screening Committee recently published a paper comparing the United Kingdom with other European countries, which is available at the following link:</p><p><a href="https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00133-3/fulltext" target="_blank">https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00133-3/fulltext</a></p><p>The paper will hopefully improve understanding of the way in which screening principles are developed and applied in new-born blood spot screening settings across the continent.</p> answering member constituency Colchester answering member printed Will Quince question first answered 08/09/2023 12:13:47 answering member 4423 label Biography information for Will Quince
	tabling member	4397 label Biography information for Peter Dowd